Common Stock, Par Value $.01 Per Share
- Symbol
- IART
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Integra LifeSciences Holdings Corporation
IARTNASDAQEQUITYCurrent
Regulation FD Disclosure
ITEM 7.01 Regulation FD Disclosure On October 9, 2026, Integra LifeSciences Holdings Corporation (the “Company”) issued a press release announcing the pricing of $450 million aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”) in a private placement. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Integra Announces Pricing of Senior Secured Notes →Company context
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care.
Current securities
Recent company filings
- Results of Operations and Financial Condition · Regulation FD DisclosureOct 2, 2026
- Regulation FD DisclosureSep 8, 2026
- SCHEDULE 13G/A - filed by PARADIGM CAPITAL MANAGEMENT INC/NY regarding INTEGRA LIFESCIENCES HOLDINGS CORPAug 13, 2026
- SCHEDULE 13G - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding INTEGRA LIFESCIENCES HOLDINGS CORPJul 31, 2026
- 10-Q filingJul 29, 2026
Registered securities in this filing
INTEGRA LIFESCIENCES HOLDINGS CORP · 8-K · Filed 2026-10-09
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
ITEM 7.01 Regulation FD Disclosure
On October 9, 2026, Integra LifeSciences Holdings Corporation (the “Company”) issued a press release announcing the pricing of $450 million aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”) in a private placement. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The Company expects that the interest rate on the Notes, together with the anticipated interest rates on other elements of the Company’s debt refinancing plan, will result in an increase in the Company’s effective interest rate that is near the high end of the anticipated 100-200 basis points range previously communicated by management.
The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of such section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 Integra Announces Pricing of Senior Secured Notes PRINCETON, N.J., October 9, 2026 - Integra LifeSciences Holdings Corporation (NASDAQ:IART) (the “Company”) today announced the pricing of $450,000,000 aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”). The Notes will be general senior secured obligations of the Company and will be guaranteed by the Company’s wholly-owned domestic subsidiaries that are guarantors under the Company’s senior secured credit facilities. The sale of the Notes is expected to close on or about October 19, 2026, subject to customary closing conditions. The Company intends to use the net proceeds from the offering of Notes, together with borrowings under a new credit facility, to refinance its existing credit facilities and pay fees and expenses in connection with the foregoing. The offering is part of a broader refinancing transaction. The Notes and the related guarantees have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction. The Notes were offered only to persons reasonably believed to be quali…
Open exhibit ↗